The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis
Switching to LDTA or TG therapy in shunting IBD patients resulted in favourable alterations in thiopurine metabolism. However, LDTA appears to have a slightly less favourable metabolite profile, with some residual 6-MMPR formation and fewer patients achieving normal 6-TGN levels compared to TG. Given the challenges associated with achieving optimal thiopurine metabolite levels with LDTA and the need for closer monitoring of 6-TGN levels, TG appears a more suitable option for thiopurine shunting IBD patients.
Authors
- Nanne K.H. de Boer (ORCID: https://orcid.org/0000-0001-8357-9887)
- Hedwig M. A. D‘Agnolo
- Ahmed B. Bayoumy (ORCID: https://orcid.org/0000-0002-5302-9312)
- Luc J. J. Derijks (ORCID: https://orcid.org/0000-0002-6038-9295)
- Chris J. Mulder (ORCID: https://orcid.org/0000-0002-6332-0365)
Institutions
- Radboud University Nijmegen (NL)
- Maastricht University (NL)
- Máxima Medisch Centrum (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1002/bcp.70112
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00